Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "NAL"

5226 News Found

Gastrointestinal disorders increasing in India
Public Health | November 25, 2021

Gastrointestinal disorders increasing in India

It is estimated that one-third of our country’s population has some form of these disorders


Alembic JV receives final approval for Mupirocin cream
Drug Approval | November 17, 2021

Alembic JV receives final approval for Mupirocin cream

The cream has an estimated market size of US $ 28 million for twelve months ending Jun 2021 according to IQVIA


International Society of Pharmacovigilance opens South Asia chapter
Public Health | November 16, 2021

International Society of Pharmacovigilance opens South Asia chapter

The aim is to support Pharmacovigilance programme across the countries in the region


NAL drone delivers Covid-19 vaccine at a remote location
Public Health | November 15, 2021

NAL drone delivers Covid-19 vaccine at a remote location

The octocopter has successfully delivered 50 vials of Covid-19 vaccines along with syringes in a special container from Chandapura PHC to Haragadde PHC


US govt places additional order of 1.4 million courses of molnupiravir
News | November 10, 2021

US govt places additional order of 1.4 million courses of molnupiravir

Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults


Mandaviya launches the sixth edition of National Formulary of India (NFI)
Public Health | October 29, 2021

Mandaviya launches the sixth edition of National Formulary of India (NFI)

The NFI is published to promote the rational use of medicines in the country.


4baseCare partners with U.S. based Cellworks for personalised cancer care
Digitisation | October 27, 2021

4baseCare partners with U.S. based Cellworks for personalised cancer care

The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.


Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
Drug Approval | October 19, 2021

Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules

The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg


Sputnik Light has 70 % efficacy against infection with Delta: Gamaleya analysis
Biotech | October 14, 2021

Sputnik Light has 70 % efficacy against infection with Delta: Gamaleya analysis

Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations


Covaxin for kids gets nod, final approval awaited
Drug Approval | October 12, 2021

Covaxin for kids gets nod, final approval awaited

The two doses of Covaxin are likely to be administered to children with a gap of 28 days